CClinicalTrials.gg
Sign In
Status unknownNCT02982473RACE-ITUpdated Aug 27, 2020

Registry of Malignant Arrhythmias and Sudden Cardiac Death - Influence of Diagnostics and Interventions

An observational study in Ventricular Tachycardia, Ventricular Fibrillation and Sudden Cardiac Death, sponsored by Universitätsmedizin Mannheim. Status unknown at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-27.

Sponsored by Universitätsmedizin Mannheim · Observational

The sponsor has not verified this record recently (last verified Aug 2020), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
3,200
Ages
18 Years and older
Sex
All
01

Study summary

The "Registry of Malignant Arrhythmias and Sudden Cardiac Death - Influence of Diagnostics and Interventions (RACE-IT)" represents a mono-centric registry of patients being hospitalized suffering from malignant arrythmias (ventricular tachycardia or fibrillation) and sudden cardiac death (SCD).

Detailed findings of patients' clinical outcome regarding mortality and co-morbidities related to the presence of invasive diagnostics or therapies including coronary angiography, percutaneous coronary intervention (PCI), electrophysiological testing (EP), catheter ablation and implanted cardiac devices (e.g. implantable cardioverter-defibrillators) will be documented. Patients will be included when being hospitalized from the year 2004 until today.

02

Conditions studied

  • Ventricular Tachycardia
  • Ventricular Fibrillation
  • Sudden Cardiac Death
  • Coronary Angiography
  • Electrophysiologic Testing (EP)
  • Catheter Ablation
  • Percutaneous Coronary Intervention (PCI)
  • Internal Cardioverter Defibrillator (ICD)
03

In context

Tachycardia

623 studies on the registry are indexed under Tachycardia; 81 are open to participants now.

This study's planned enrollment of 3,200 is above the median of 149 across 208 observational studies indexed under Tachycardia.

Browse Tachycardia studies →

Lead sponsor

Universitätsmedizin Mannheim is the lead sponsor of 75 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients being hospitalized with diagnoses of ventricular tachycardia, ventricular fibrillation and/or sudden cardiac death at the First Department of Medicine, University Medical Centre Mannheim, Germany.

Inclusion criteria

Hospitalization due to:

  • ventricular tachycardia
  • ventricular fibrillation
  • sudden cardiac death

Exclusion criteria

Exclusion Criteria:

  • not diagnosed with one or more of the above
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
3,200 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Incidence of ventricular arrythmias (i.e. ventricular fibrillation, ventricular tachykardia, asystole, SCD)

    Time frame: Through study completion, potentially up to 12 years, depending on patient inclusion/first event and patients lifetime

Secondary outcomes

  1. Incidence of coronary artery disease (CAD) and PCI in patients with VF/VT/SCD

    Time frame: Through study completion, potentially up to 12 years, depending on patient inclusion/first event and patients lifetime

  2. Incidence of invasive electrophysiologic testing (EP) and catheter ablation

    Time frame: Through study completion, potentially up to 12 years, depending on patient inclusion/first event and patients lifetime

  3. Incidence of treatment with cardiac devices (i.e. ICD, CCM, CRT-D)

    Time frame: Through study completion, potentially up to 12 years, depending on patient inclusion/first event and patients lifetime

  4. Incidences of recurrent malignant tachycardias, all-cause mortality, arrhythmia-related death, re-PCI/ACVB, re-ablation, further therapy with cardiac devices

    Time frame: Through study completion, potentially up to 12 years, depending on patient inclusion/first event and patients lifetime

07

Study locations

1 of 1 sites recruiting
  • First Department of Medicine, University Medical Centre Mannheim
    Mannheim, 68167, Germany
    Recruiting
08

References and documents

Publications

  • Weidner K, Behnes M, Schupp T, Hoppner J, El-Battrawy I, Ansari U, Saleh A, Taton G, Reiser L, Bollow A, Reichelt T, Ellguth D, Engelke N, Bertsch T, Grosse Meininghaus D, Hoffmann U, Akin I. Cardiac disease and prognosis associated with ventricular tachyarrhythmias in young adults and adults. BMC Cardiovasc Disord. 2022 Mar 31;22(1):136. doi: 10.1186/s12872-022-02552-6. PubMed 35361107 ↗
  • Rusnak J, Behnes M, Schupp T, Lang S, Reiser L, Taton G, Bollow A, Reichelt T, Ellguth D, Engelke N, Ansari U, El-Battrawy I, Bertsch T, Nienaber CA, Akin M, Mashayekhi K, Weiss C, Borggrefe M, Akin I. Statin therapy is associated with improved survival in patients with ventricular tachyarrhythmias. Lipids Health Dis. 2019 May 24;18(1):119. doi: 10.1186/s12944-019-1011-x. PubMed 31122256 ↗
  • Schupp T, Behnes M, Weiss C, Nienaber C, Lang S, Reiser L, Bollow A, Taton G, Reichelt T, Ellguth D, Engelke N, Ansari U, El-Battrawy I, Bertsch T, Akin M, Mashayekhi K, Borggrefe M, Akin I. Beta-Blockers and ACE Inhibitors Are Associated with Improved Survival Secondary to Ventricular Tachyarrhythmia. Cardiovasc Drugs Ther. 2018 Aug;32(4):353-363. doi: 10.1007/s10557-018-6812-z. PubMed 30074111 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02982473
Lead sponsor
Universitätsmedizin Mannheim
Responsible party
Michael Behnes (Sub-PI, Universitätsmedizin Mannheim) — Principal investigator
First posted
Dec 5, 2016
Start date
Apr 2016
Primary completion
Dec 2021 (estimated)
Completion
Jul 2022 (estimated)
Last update
Aug 27, 2020

Study contacts

Ibrahim Akin, Prof. Dr.
Contact
ibrahim.akin@umm.de
+49 621 383 5229
Michael Behnes, Dr. med.
Contact
michael.behnes@umm.de
+49 621 383 6239
Ibrahim Akin, Prof. Dr.
principal investigator · First Deparment of Medicine, University Medical Centre Mannheim (UMM), Germany; Theodor-Kutzer-Ufer 1-3; 61867 Mannheim, Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Tachycardia→

Other studies from this sponsor

Universitätsmedizin Mannheim

Start the discussion